Lerapolturev (PVSRIPO) in GBM
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this research study is to determine the safety and efficacy of administering two doses of lerapolturev in residual disease (within tumor margins) after surgery, followed later by repeated injections of lerapolturev in the subcutaneous area (under the skin) around the lymph nodes of the head and neck for adult patients diagnosed with recurrent glioblastoma at the Preston Robert Tisch Brain Tumor Center (PRTBTC) at Duke.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony glejak wielopostaciowy (nowotwór mózgu stopnia 4) który powrócił po leczeniu
- •Ogólny stan zdrowia pozwalający na leczenie (wynik Karnofskiego co najmniej 70%)
- •Wystarczająca liczba płytek krwi (co najmniej 100 000) do uczestnictwa w badaniu
- •Wystarczająca liczba białych krwinek (neutrofili co najmniej 1000)
- •Prawidłowe wyniki testów wątroby i nerek
- •Przeprowadzona szczepionka przeciw poliomyelitis w ciągu ostatnich 6 tygodni
- •Możliwość wykonania rezonansu magnetycznego mózgu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Duke University Medical Center
Durham, United States
Trial contact
Madison Shoaf, MD
Stevie Threatt
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/21/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.